November 10th, 2026Updates on CTx-1301, NDA Resubmission After FDA Complete Response LetterCingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requestsRead more
November 17th, 2026Mixed Results From Phase 3 Data for AR1001 in Alzheimer DiseaseNew phase 3 data for a PDE-5 inhibitor in Alzheimer disease.Read more
November 16th, 2026Morning Rounds: News From November 9-16Review news from the last week in pharmacology, legislation, and research. Read more
November 13th, 2026Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and SchizophreniaReview the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.Read more
November 12th, 2026Reviewing Roluperidone as Treatment for Negative Symptoms in SchizophreniaMinerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.Read more
November 4th, 2026The Ozempic Dilemma: Promises and Pitfalls in PsychiatryGLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.Read more